Which of the following best describes the ongoing monitoring of drug safety after approval?

• A. Continued pharmacovigilance as part of postmarketing safety
• B. Preclinical animal testing
• C. Manufacturing facility audits only
• D. Marketing campaigns

Answer: (A)

Ongoing monitoring of drug safety after approval is pharmacovigilance, or postmarketing surveillance. This involves collecting and analyzing reports of adverse events from clinicians, patients, and sponsors, evaluating whether there is a real safety signal, and taking actions to protect patients—such as updating labeling, issuing safety communications, or implementing use restrictions. Trials before approval can’t detect all rare or long-term effects, so continuing vigilance after a drug is on the market ensures the benefit–risk balance remains favorable in real-world use. In contrast, preclinical animal testing happens before humans; manufacturing facility audits check quality systems rather than ongoing patient safety, and marketing campaigns do not address safety monitoring.